Jiangxi Food and Drug Administration releases good news: products of innovative review channels are available for review

Recently, Jiangxi Provincial Drug Administration issued the "Several Policies and Measures for Jiangxi Provincial Drug Administration to Support the High-quality Leap-forward Development of the Biomedical Industry in Nanchang", and proposed 18 specific measures from four aspects to help the high-quality biomedical industry in Nanchang.
Quality development
.
Several policies and measures clearly support the innovative development of the Nanchang biopharmaceutical industry.
It is mentioned that a new drug application service platform will be established to fully support drug registration and application as soon as possible to enter the priority review and approval channel of the National Medical Products Administration; for products that enter the innovation review channel, a green channel will be opened.
Priority review is implemented; at the same time, it is also clarified that products of innovative review channels are available for review, and the technical review time limit shall not exceed 20 working days in principle
.
It can be seen that in the future, the speed of product technical review by Nanchang pharmaceutical companies through the innovation review channel is expected to be further improved, and the launch of new drugs will also be accelerated
.
At the same time, a number of measures also support the development of Nanchang biomedical industry clusters, mentioning that it will strengthen the guidance and assistance to the Chinese Medicine Science and Technology City, Jinxian Industrial Park, and the Xiaolan Industrial Park; promote the implementation of the industrial planning and construction of the "Chinese Medicine Science and Technology City" Work to cultivate the traditional Chinese medicine industry cluster in the "Technological Innovation City of Traditional Chinese Medicine"
.
Traditional Chinese medicine is a great creation of the Chinese nation.
It has made outstanding contributions to the improvement of human health.
In recent years, the cause of Chinese medicine has developed rapidly and has promising prospects
.
In the face of new opportunities, it has become the mission and responsibility of the new era to follow the law of development of traditional Chinese medicine, inherit the essence, maintain integrity and innovation, and promote the modernization and high-quality development of industrialization of traditional Chinese medicine
.
In order to support the inheritance, innovation and development of traditional Chinese medicine in Nanchang, a number of measures propose to support the development, use and promotion of traditional Chinese medicine preparations in medical institutions in Nanchang, and encourage key Chinese medicine manufacturers and R&D institutions in Nanchang to increase the development of classic prescriptions
.
The biopharmaceutical industry is an important industry related to the national economy and people’s livelihood.
According to statistics, the scale of China’s biopharmaceutical industry will be 3.
57 trillion yuan in 2020.
According to the current development trend, it is expected to exceed 4 trillion yuan by 2022 and exceed 5 trillion yuan in 2025.
Trillion yuan, with an average annual growth rate of about 8%
.
Nanchang attaches great importance to the development of the biopharmaceutical industry.
This year, the overall scale of the industry has achieved breakthroughs.
Leading companies including Haoran Biotechnology and Jimintong continue to grow bigger and stronger.
Among them, Jimintong's operating income in the first September of this year increased by 143% year-on-year.

.
At present, the Nanchang biomedical industry has formed a development pattern of "two-city innovation leadership and three-zone high-efficiency synergy"
.
Shuangcheng, namely the core area of ​​Jiangzhong Medicine Valley of China (Nanchang) Traditional Chinese Medicine Science and Technology City and China (Nanchang) Modern Medical Device Science and Technology City; three districts, namely Nanchang High-tech Zone Pharmaceutical Headquarters and Marketing Cluster, Xiaolan Modern Pharmaceutical Production Cluster District, Nanchang Economic and Technological Development Zone Pharmaceutical Industry Cluster District
.
According to statistics from the Nanchang Bureau of Industry and Information Technology, Nanchang's biomedical industry ranked first in the province in terms of industrial scale from January to October
.
The added value of the regulated industries increased by 12.
8% year-on-year, and realized operating income of 28.
47 billion yuan, accounting for a quarter of the province, a year-on-year increase of 22%
.
It is reported that in order to seize the window of opportunity for the development of emerging industries and accelerate the development of the Nanchang biopharmaceutical industry in scale, agglomeration, and high-end development, the Nanchang Municipal Bureau of Industry and Information Technology is following the requirements of "one industry, one policy" and "one enterprise, one policy".
Research and formulate a number of policies to accurately support the biomedical industry
.
It is estimated that in 2021, the operating income of the biomedical industry enterprises above designated size in the city will reach about 35 billion yuan
.